HLTH22: Rimidi Launches New Respiratory Module to Deliver Better Treatment

What You Should Know:

Rimidi launches its new Respiratory Module through integration with Teva Pharmaceuticals’ digital inhalers that be integrated into healthcare provider workflows, enhancing respiratory care and population health management.

– This new module allows providers to comprehend the full picture of the patient’s disease status both in the clinic and at home – giving clinical teams the tools they need to make personalized, predictive care decisions and improve outcomes.

Why It Matters

Over 500 million people globally suffer from respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). In many cases, patients with these respiratory conditions also have cardiometabolic disorders like hypertension, obesity and diabetes, which can create additional health complications and lead to greater healthcare expenses. Rimidi’s Respiratory Module, which complements the company’s full suite of disease modules, allows providers to comprehend the full picture of the patient’s disease status both in the clinic and at home. As a result, staff are better empowered and equipped to make personalized, predictive care decisions and improve outcomes.